$XRAY

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

Original reporting
Published Sep 3, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding — source image
Decision brief

The 30-second read

$XRAYNeutralMed
01

Why it matters

The earnings beat on profitability but miss on revenue creates a split narrative, likely leading to modest price movement and heightened volatility.

02

Market read

Earnings release provides fresh data for traders; relevance is moderate due to mixed signals.

03

What to watch

The $44 M tariff refunds and ERP implementation costs could be one‑time items; future quarters may revert to weaker cash flow.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

Dentsply Sirona reported Q2 2026 results with profit after a loss year‑over‑year, while sales continued to decline.

Company-level read

Ticker impact

$XRAYNeutralMedium confidence
Context

Q2 2026 earnings showed a swing to $37 M net income despite a 4.1% sales decline, marking the first report of this turnaround.

Expected impact

Potential modest upside if guidance holds, but volatility likely as investors weigh margin gains versus revenue decline.

Evidence & confidence

Margins are expanding and cash flow is strong, yet revenue contraction and elevated short interest suggest mixed market reaction.

Market effects

Dental equipment sector may see pressure on peers with similar revenue declines, while margin‑focused investors could rotate into higher‑margin players.

North American dental market faces headwinds; Canadian partnership expansion offers limited regional boost.

Limited to healthcare equipment niche; no broad market impact.

Counterpoint

Short sellers may be over‑positioned given the strong cash generation and margin expansion, presenting a potential short‑cover rally.

Key entities

  • Dentsply Sirona

    Dental equipment manufacturer (NASDAQ:XRAY).

Related articles

$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.